Nabriva Therapeutics plc (NBRV) financial statements (2021 and earlier)

Company profile

Business Address 56 FITZWILLIAM SQUARE
DUBLIN, 2
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:871028784
Cash and cash equivalents861028733
Short-term investments00051
Other undisclosed cash, cash equivalents, and short-term investments0(0)00
Receivables1456
Inventory, net of allowances, customer advances and progress billings1   
Inventory1   
Prepaid expense1121
Contract with customer, asset 2
Other undisclosed current assets20(0)(0)
Total current assets:911099491
Noncurrent Assets
Nontrade receivables0000
Property, plant and equipment2111
Intangible assets, net (including goodwill)0000
Intangible assets, net (excluding goodwill)0000
Deferred tax assets, net  1
Total noncurrent assets:3223
TOTAL ASSETS:941109693
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17181316
Accounts payable5353
Accrued liabilities1215813
Taxes payable   0
Total current liabilities:17181316
Noncurrent Liabilities
Long-term debt and lease obligation35240 
Long-term debt, excluding current maturities35240 
Liabilities, other than long-term debt2000
Other liabilities2000
Total noncurrent liabilities:362400
Total liabilities:53421416
Stockholders' equity
Stockholders' equity attributable to parent, including:41698277
Common stock11 3
Additional paid in capital517462361279
Accumulated other comprehensive income0000
Accumulated deficit(477)(394)(279)(205)
Other undisclosed stockholders' equity attributable to parent  0 
Total stockholders' equity:41698277
TOTAL LIABILITIES AND EQUITY:941109693

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues91056
Revenue, net56
Cost of revenue
(Cost of Goods and Services Sold)
(0)   
Gross profit:91056
Operating expenses(89)(124)(79)(62)
Operating loss:(79)(114)(74)(55)
Nonoperating income (expense)0(0)0(1)
Investment income, nonoperating000 
Other nonoperating income (expense)0(0) 0
Interest and debt expense(4)(0)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes   0
Loss from continuing operations before equity method investments, income taxes:(83)(115)(73)(56)
Other undisclosed income from continuing operations before income taxes  0 
Loss from continuing operations before income taxes:(83)(115)(73)(56)
Income tax expense (benefit)(0)(0)(1)1
Net loss available to common stockholders, diluted:(83)(115)(74)(55)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(83)(115)(74)(55)
Other comprehensive income  0 
Comprehensive loss:(83)(115)(74)(55)
Other undisclosed comprehensive income, net of tax, attributable to parent   0
Comprehensive loss, net of tax, attributable to parent:(83)(115)(74)(55)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: